Concepts (177)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Phage Therapy | 3 | 2019 | 63 | 1.59 | Why? |
| Air Microbiology | 2 | 2021 | 1322 | 0.84 | Why? |
| Staphylococcus epidermidis | 1 | 2019 | 53 | 0.76 | Why? |
| Respiratory Physiological Phenomena | 1 | 2020 | 157 | 0.76 | Why? |
| Prodrugs | 1 | 2021 | 264 | 0.75 | Why? |
| Bacteriophages | 2 | 2019 | 268 | 0.72 | Why? |
| Pancreatic Pseudocyst | 1 | 2017 | 23 | 0.71 | Why? |
| Pancreatitis, Acute Necrotizing | 1 | 2017 | 47 | 0.68 | Why? |
| Acinetobacter Infections | 2 | 2019 | 273 | 0.58 | Why? |
| Health Occupations | 1 | 2018 | 235 | 0.58 | Why? |
| Acinetobacter baumannii | 2 | 2019 | 378 | 0.57 | Why? |
| Prosthesis-Related Infections | 1 | 2019 | 302 | 0.57 | Why? |
| Dysbiosis | 1 | 2018 | 685 | 0.47 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 711 | 0.47 | Why? |
| Schools, Medical | 1 | 2018 | 793 | 0.42 | Why? |
| Heart-Assist Devices | 1 | 2019 | 812 | 0.41 | Why? |
| Staphylococcal Infections | 1 | 2019 | 1099 | 0.38 | Why? |
| Microbiota | 1 | 2018 | 1240 | 0.35 | Why? |
| Anti-HIV Agents | 5 | 2019 | 2209 | 0.35 | Why? |
| Evidence-Based Medicine | 1 | 2021 | 3228 | 0.35 | Why? |
| Malaria, Falciparum | 1 | 2012 | 377 | 0.34 | Why? |
| HIV Infections | 7 | 2019 | 11620 | 0.32 | Why? |
| Mozambique | 2 | 2018 | 205 | 0.29 | Why? |
| HIV-1 | 4 | 2019 | 3365 | 0.24 | Why? |
| Drug Resistance, Multiple, Bacterial | 3 | 2019 | 1115 | 0.23 | Why? |
| Zika Virus | 3 | 2019 | 1924 | 0.23 | Why? |
| Education, Medical | 1 | 2018 | 2461 | 0.22 | Why? |
| Zika Virus Infection | 3 | 2019 | 1920 | 0.21 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 1 | 2021 | 8843 | 0.19 | Why? |
| Wound Infection | 1 | 2019 | 66 | 0.19 | Why? |
| Sneezing | 1 | 2020 | 173 | 0.19 | Why? |
| Receptors, CXCR4 | 1 | 2019 | 83 | 0.19 | Why? |
| Anti-Bacterial Agents | 2 | 2019 | 10083 | 0.19 | Why? |
| Vaginosis, Bacterial | 1 | 2018 | 51 | 0.18 | Why? |
| Biomedical Research | 2 | 2018 | 5270 | 0.18 | Why? |
| SARS Virus | 1 | 2021 | 13021 | 0.17 | Why? |
| Nevirapine | 2 | 2019 | 57 | 0.17 | Why? |
| Masks | 1 | 2020 | 8528 | 0.17 | Why? |
| Caco-2 Cells | 1 | 2021 | 1236 | 0.17 | Why? |
| Antiretroviral Therapy, Highly Active | 2 | 2017 | 952 | 0.17 | Why? |
| Speech | 1 | 2020 | 241 | 0.17 | Why? |
| CD4 Antigens | 1 | 2018 | 306 | 0.17 | Why? |
| Adenosine | 1 | 2021 | 509 | 0.17 | Why? |
| Gallstones | 1 | 2017 | 64 | 0.17 | Why? |
| Minocycline | 1 | 2017 | 101 | 0.16 | Why? |
| Cricetinae | 2 | 2021 | 3344 | 0.16 | Why? |
| Drug Resistance, Viral | 3 | 2019 | 1083 | 0.15 | Why? |
| Inhalation Exposure | 1 | 2020 | 405 | 0.15 | Why? |
| RNA Helicases | 1 | 2019 | 413 | 0.15 | Why? |
| Vagina | 1 | 2018 | 327 | 0.15 | Why? |
| Respiration | 1 | 2020 | 729 | 0.14 | Why? |
| Antibody-Dependent Enhancement | 1 | 2018 | 413 | 0.14 | Why? |
| Pseudomonas Infections | 1 | 2019 | 425 | 0.14 | Why? |
| Lipids | 1 | 2021 | 1079 | 0.14 | Why? |
| Pseudomonas aeruginosa | 1 | 2019 | 652 | 0.13 | Why? |
| Treatment Failure | 1 | 2019 | 2106 | 0.13 | Why? |
| Parasitemia | 1 | 2012 | 88 | 0.12 | Why? |
| High-Throughput Screening Assays | 1 | 2021 | 1783 | 0.12 | Why? |
| Capacity Building | 1 | 2018 | 683 | 0.12 | Why? |
| Health Personnel | 2 | 2021 | 29646 | 0.11 | Why? |
| Precision Medicine | 1 | 2022 | 1477 | 0.11 | Why? |
| Blood | 1 | 2012 | 274 | 0.11 | Why? |
| Dengue Virus | 1 | 2018 | 910 | 0.11 | Why? |
| Intersectoral Collaboration | 1 | 2018 | 1065 | 0.11 | Why? |
| Humans | 27 | 2022 | 930598 | 0.10 | Why? |
| Asymptomatic Diseases | 1 | 2021 | 3444 | 0.09 | Why? |
| Drug Discovery | 2 | 2019 | 3092 | 0.09 | Why? |
| Asymptomatic Infections | 2 | 2020 | 7218 | 0.09 | Why? |
| Computer Simulation | 2 | 2019 | 4982 | 0.08 | Why? |
| Peptides | 1 | 2019 | 2513 | 0.08 | Why? |
| Molecular Docking Simulation | 2 | 2019 | 6902 | 0.08 | Why? |
| Universities | 1 | 2021 | 4374 | 0.08 | Why? |
| Cough | 1 | 2020 | 4891 | 0.08 | Why? |
| Dengue | 1 | 2018 | 1565 | 0.08 | Why? |
| Gastrointestinal Microbiome | 1 | 2018 | 1961 | 0.07 | Why? |
| Aerosols | 1 | 2021 | 5393 | 0.07 | Why? |
| Adenosine Monophosphate | 1 | 2021 | 5652 | 0.06 | Why? |
| Alanine | 1 | 2021 | 5687 | 0.06 | Why? |
| Molecular Structure | 2 | 2019 | 1539 | 0.06 | Why? |
| Antiviral Agents | 3 | 2022 | 41703 | 0.06 | Why? |
| Virus Internalization | 2 | 2018 | 7921 | 0.06 | Why? |
| Polymerase Chain Reaction | 2 | 2021 | 6740 | 0.06 | Why? |
| Structure-Activity Relationship | 2 | 2019 | 2219 | 0.06 | Why? |
| Viral Nonstructural Proteins | 1 | 2019 | 4810 | 0.05 | Why? |
| Mutation | 2 | 2019 | 12376 | 0.05 | Why? |
| CD4 Lymphocyte Count | 2 | 2018 | 1517 | 0.05 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.05 | Why? |
| Cell Line | 3 | 2019 | 12040 | 0.05 | Why? |
| Emtricitabine | 1 | 2019 | 202 | 0.05 | Why? |
| Venezuela | 1 | 2018 | 172 | 0.05 | Why? |
| Chromatin | 1 | 2018 | 107 | 0.04 | Why? |
| Lopinavir | 1 | 2012 | 4308 | 0.04 | Why? |
| Quantitative Structure-Activity Relationship | 1 | 2018 | 209 | 0.04 | Why? |
| Ritonavir | 1 | 2012 | 4212 | 0.04 | Why? |
| Aged | 4 | 2021 | 215776 | 0.04 | Why? |
| Culicidae | 1 | 2018 | 239 | 0.04 | Why? |
| Male | 8 | 2021 | 367725 | 0.04 | Why? |
| Animals | 3 | 2021 | 78931 | 0.04 | Why? |
| Time Factors | 1 | 2020 | 31397 | 0.04 | Why? |
| Receptor, Interferon alpha-beta | 1 | 2018 | 610 | 0.04 | Why? |
| Pandemics | 3 | 2021 | 389249 | 0.04 | Why? |
| Tenofovir | 1 | 2019 | 449 | 0.04 | Why? |
| Female | 10 | 2021 | 380317 | 0.04 | Why? |
| Technology | 1 | 2021 | 812 | 0.04 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.04 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.03 | Why? |
| Models, Molecular | 2 | 2019 | 7616 | 0.03 | Why? |
| Societies, Scientific | 1 | 2017 | 414 | 0.03 | Why? |
| California | 1 | 2021 | 2047 | 0.03 | Why? |
| Ligands | 1 | 2019 | 1300 | 0.03 | Why? |
| Klebsiella pneumoniae | 1 | 2019 | 658 | 0.03 | Why? |
| Myeloid Cells | 1 | 2018 | 808 | 0.03 | Why? |
| Adult | 8 | 2021 | 244371 | 0.03 | Why? |
| Air Pollution, Indoor | 1 | 2020 | 816 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2018 | 2324 | 0.03 | Why? |
| Viremia | 1 | 2018 | 1020 | 0.03 | Why? |
| Communicable Disease Control | 1 | 2020 | 29620 | 0.03 | Why? |
| Endpoint Determination | 1 | 2012 | 344 | 0.03 | Why? |
| Prevalence | 1 | 2012 | 25773 | 0.03 | Why? |
| Basic Reproduction Number | 1 | 2021 | 2676 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2019 | 3776 | 0.02 | Why? |
| Cystic Fibrosis | 1 | 2019 | 1104 | 0.02 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1573 | 0.02 | Why? |
| Antibodies, Viral | 2 | 2018 | 51949 | 0.02 | Why? |
| Death | 1 | 2012 | 334 | 0.02 | Why? |
| Whole Genome Sequencing | 1 | 2019 | 3239 | 0.02 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2018 | 2483 | 0.02 | Why? |
| Vaccines, Synthetic | 1 | 2021 | 3231 | 0.02 | Why? |
| Mice, Inbred C57BL | 1 | 2018 | 5542 | 0.02 | Why? |
| Lung Transplantation | 1 | 2019 | 1554 | 0.02 | Why? |
| Adolescent | 2 | 2021 | 86841 | 0.02 | Why? |
| Prospective Studies | 1 | 2012 | 43301 | 0.02 | Why? |
| Cross Reactions | 1 | 2018 | 4374 | 0.02 | Why? |
| Immunity | 1 | 2018 | 2651 | 0.02 | Why? |
| Adaptive Immunity | 1 | 2018 | 2585 | 0.02 | Why? |
| Young Adult | 2 | 2021 | 93724 | 0.02 | Why? |
| Drug Evaluation, Preclinical | 1 | 2018 | 3347 | 0.02 | Why? |
| Cytokines | 2 | 2018 | 15010 | 0.02 | Why? |
| Drug Design | 1 | 2018 | 2627 | 0.02 | Why? |
| Binding Sites | 1 | 2018 | 6201 | 0.02 | Why? |
| Acute Disease | 1 | 2018 | 6029 | 0.02 | Why? |
| Molecular Diagnostic Techniques | 1 | 2021 | 4239 | 0.02 | Why? |
| Antibody Formation | 1 | 2018 | 4038 | 0.02 | Why? |
| Cross-Sectional Studies | 1 | 2012 | 53120 | 0.02 | Why? |
| Computational Biology | 1 | 2018 | 4514 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2018 | 9893 | 0.02 | Why? |
| Africa | 1 | 2012 | 2986 | 0.02 | Why? |
| Viral Load | 2 | 2018 | 15850 | 0.02 | Why? |
| Middle Aged | 3 | 2021 | 270681 | 0.02 | Why? |
| Kaplan-Meier Estimate | 1 | 2012 | 4260 | 0.02 | Why? |
| Medication Adherence | 1 | 2012 | 1270 | 0.01 | Why? |
| Protein Binding | 1 | 2018 | 11430 | 0.01 | Why? |
| T-Lymphocytes | 1 | 2018 | 6670 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2018 | 10998 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2021 | 22971 | 0.01 | Why? |
| Travel | 1 | 2018 | 7220 | 0.01 | Why? |
| Phylogeny | 1 | 2018 | 13341 | 0.01 | Why? |
| Antibodies, Monoclonal | 1 | 2018 | 8041 | 0.01 | Why? |
| HIV | 1 | 2006 | 1116 | 0.01 | Why? |
| Mice | 1 | 2018 | 21357 | 0.01 | Why? |
| Infant | 1 | 2021 | 30274 | 0.01 | Why? |
| Drug Monitoring | 1 | 2006 | 1408 | 0.01 | Why? |
| Hepatitis B | 1 | 2006 | 888 | 0.01 | Why? |
| Genome, Viral | 1 | 2019 | 13157 | 0.01 | Why? |
| Child, Preschool | 1 | 2021 | 36283 | 0.01 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.01 | Why? |
| Hepatitis C | 1 | 2006 | 1514 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2018 | 21571 | 0.01 | Why? |
| Disease Outbreaks | 1 | 2021 | 27595 | 0.01 | Why? |
| Treatment Outcome | 1 | 2019 | 51732 | 0.01 | Why? |
| Child | 1 | 2021 | 70012 | 0.01 | Why? |
| Antibodies, Neutralizing | 1 | 2018 | 25288 | 0.01 | Why? |
| Aged, 80 and over | 1 | 2021 | 88759 | 0.01 | Why? |
| United States | 1 | 2017 | 46150 | 0.01 | Why? |
| Tuberculosis | 1 | 2006 | 2895 | 0.01 | Why? |
| Pregnancy | 1 | 2006 | 23879 | 0.00 | Why? |
| Pregnancy Complications, Infectious | 1 | 2006 | 11559 | 0.00 | Why? |
Schooley's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(177)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(81)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_